Xiaokui Zhang

Dr. Xiaokui Zhang has 15+ years of experience in leading discovery, research and development in the biopharmaceutical industry to advance research stage programs into early clinical development. She joined Celularity in August 2017 as EVP, Chief Scientific Offer to head Research & Development operations in immuno-oncology and functional regeneration. Her previous roles included Senior Director of Research at Celgene Cellular Therapeutics where she led the development of novel immunotherapy candidates derived from placental progenitor cells and initiated clinical trials. She holds a B.Sc. in Physiology from Nanjing University, Ph.D. in Molecular Cell Biology from the Rockefeller University with further post-doctoral training in the Functional Genomics Department of Novartis Pharmaceuticals.

Xiaokui Zhang

THE NEXT
EVOLUTION IN
CELLULAR
MEDICINE

Contact Us

How To Reach Us

Subscribe For Updates

Xiaokui Zhang

CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy

THE NEXT EVOLUTION IN CELLULAR MEDICINE

Contact Us

How To Reach Us

Subscribe For Updates

THE NEXT
EVOLUTION IN
CELLULAR
MEDICINE